None
DE
Recent Research Analysts’ Ratings Updates for Biogen (BIIB)
['Ethan Ryder']
Ticker Report
Biogen (NASDAQ: BIIB) recently received a number of ratings updates from brokerages and research firms:9/20/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
9/12/2025 – Biogen had its price target raised by analysts at Piper Sandler from $115.00 to $118.00.
8/14/2025 – Biogen had its price target raised by analysts at Piper Sandler from $115.00 to $118.00.
8/1/2025 – Biogen had its price target raised by analysts at Royal Bank Of Canada from $208.00 to $219.00.
8/1/2025 – Biogen had its price target raised by analysts at Citigroup Inc. from $125.00 to $135.00.
['analysts'
'target'
'recent'
'shares'
'ratings'
'biib'
'stock'
'rating'
'transaction'
'price'
'research'
'raised'
'updates'
'biogen'
'sold']